U.S. markets close in 1 hour 14 minutes
  • S&P 500

    4,415.63
    +28.47 (+0.65%)
     
  • Dow 30

    35,054.86
    +216.70 (+0.62%)
     
  • Nasdaq

    14,732.47
    +51.40 (+0.35%)
     
  • Russell 2000

    2,217.97
    +2.48 (+0.11%)
     
  • Crude Oil

    70.50
    -0.76 (-1.07%)
     
  • Gold

    1,813.30
    -8.90 (-0.49%)
     
  • Silver

    25.60
    +0.02 (+0.10%)
     
  • EUR/USD

    1.1872
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.1770
    +0.0030 (+0.26%)
     
  • GBP/USD

    1.3912
    +0.0028 (+0.20%)
     
  • USD/JPY

    109.1100
    -0.1990 (-0.18%)
     
  • BTC-USD

    38,042.33
    -1,641.93 (-4.14%)
     
  • CMC Crypto 200

    928.26
    -15.18 (-1.61%)
     
  • FTSE 100

    7,105.72
    +24.00 (+0.34%)
     
  • Nikkei 225

    27,641.83
    -139.19 (-0.50%)
     

Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020

·1 min read

WESTLAKE VILLAGE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Arcutis management will participate in a fireside chat presentation during the Cantor Fitzgerald Global Healthcare Conference 2020 taking place Sept. 15-17, 2020.

Details for the presentation are as follows:
Cantor Fitzgerald Global Healthcare Conference 2020
Presentation Date: Thursday, Sept. 17, 2020
Presentation Time: 7:40 a.m. PT / 10:40 a.m. ET

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations . Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Arcutis - Bioscience, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Investors and Media:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740